New Perspectives on Diagnosis and Treatment of EGFR Exon 20 Insertion–NSCLC

Discover new developments in the diagnosis and treatment of EGFR exon-20 Insertion–Mutant NSCLC and assess emerging efficacy and safety data on novel targeted therapies. This activity features expert insights from Helena Yu, MD, Memorial Sloan Kettering Cancer Center, and Maria Arcila, MD, Memorial Sloan Kettering Cancer Center.

This activity is also available as a podcast.

An estimated 235,760 new cases of lung cancer are reported in the United States annually, and 131,880 people die of the disease. Approximately 84% of cases are classified as non-small cell lung cancer (NSCLC) (ACS, 2021). The most frequent genomic aberration among patients with NSCLC is the epidermal growth factor receptor (EGFR) mutation, approximately 2%-10% of which are exon 20 insertion mutations (Kumari et al, 2019; Dersarkissian et al, 2019). Exon 20 insertion mutations are a heterogenous group frequently associated with resistance to first- and second-line EGFR tyrosine kinase inhibitor (TKI) therapy (NCCN, 2021). Currently, there are no approved therapies specifically designed to treat EGFR exon 20 insertion–mutant NSCLC (LCRF, 2020). There is an unmet need to develop effective targeted therapies to improve outcomes and quality of life in patients with this disease.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Discuss the predictive/prognostic significance of EGFR exon 20 insertions in NSCLC
Evaluate the benefits and limitations of polymerase chain reaction and next-generation sequencing in diagnosis of EGFR exon 20 insertion–mutant NSCLC
Assess emerging efficacy and safety data on novel targeted therapies for advanced EGFR exon 20 insertion–mutant NSCLC